Type 2 diabetes is associated with faster formation of poorly lysable, denser fibrin clots and elevated cellular fibronectin (cFn), a marker of vascular injury. We investigated whether cFn affects clot properties in type 2 diabetes. In 200 consecutive patients with type 2 diabetes and 100 control subjects matched for age and sex, we determined plasma cFn along with clot formation and degradation using turbidimetric and permeability assays. Diabetic patients had elevated cFn (median, 3.99 [interquartile range, 2.87–4.81] µg/ml]), increased clot density (MaxAbsC) and prolonged lysis time (LysT) compared with those without type 2 diabetes (all p<0.01). Diabetic patients with documented cardiovascular disease (CVD, n=127, 63.5 %) had increased cFn (4.53 [3.68–4.95] µg/ml), decreased clot permeability (Ks) and increased MaxAbsC compared with those without CVD (all p<0.001). Diabetic patients with cFn in the top quartile (>4.81 µg/ml) were two times more likely to have CVD compared with those in the lowest quartile (odds ratio 1.80, 95 % confidence interval 1.41–2.46, p<0.001). No differences in cFn were observed in relation to microvascular complications. After adjustment for potential confounders, cFn accounted for 10.2 % of variance in Ks, 18.2 % of variance in clot density and 10.2 % of variance in AUC in diabetic patients. This study shows that elevated cFn is associated with unfavourably modified clot properties in type 2 diabetes, especially with concomitant CVD, which indicates novel links between vascular injury and prothrombotic alterations in diabetes. Coagulation, cellular fibronectin, type 2 diabetes, cardiovascular disease.
Supplementary Material to this article is available online at www.thrombosis-online.com.
6
Bochenek M,
Zalewski J,
Sadowski J.
et al. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis 2013; 35: 264-270.
7
Undas A,
Wiek I,
Stepien E.
et al. Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome. Diabetes Care 2008; 31: 1590-1595.
8
Konieczynska M,
Fil K,
Bazanek M.
et al. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost 2014; 111: 685-693.
9
Hess K,
Alzahrani SH,
Price JF.
et al. Hypofibrinolysis in type 2 diabetes: The role of the inflammatory pathway and complement C3. Diabetologia 2014; 57: 1737-1741.
11
Undas A,
Ariëns RA.
Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
12
Soma P,
Pretorius E.
Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus. Cardiovasc Diabetol 2015; 14: 96
13
Pretorius E,
Bester J,
Vermeulen N.
et al. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol 2015; 14: 30
15
Walus-Miarka M,
Wolkow P,
Cyganek K.
et al. Altered fibrin-clot properties are associated with retinopathy in type 2 diabetes mellitus. Diabetes Metab 2012; 38: 462-465.
17
To WS,
Midwood KS.
Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 2011; 04: 21
18
Corbett SA,
Lee L,
Wilson CL.
et al. Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. J Biol Chem 1997; 272: 2499-2505.
21
van Keulen JK,
de Kleijn DP,
Nijhuis MM.
et al. Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis 2007; 195: e83-91.
23
Undas A,
Szuldrzynski K,
Stepien E.
et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-557.
24
Undas A,
Zawilska K,
Ciesla-Dul M.
et al. Altered fibrin clot structure / function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4279.
25
Carter AM,
Cymbalista CM,
Spector TD.
et al. Heritability of clot formation, morphology, and lysis: The EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-2789.
31
Makogonenko E,
Tsurupa G,
Ingham K.
et al. Interaction of Fibrin(ogen) with Fibronectin: Further Characterization and Localization of the Fibronectin-Binding Site. Biochemistry 2002; 41: 7907-7913.
35
Maurer E,
Schaff M,
Receveur N.
et al. Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. Thromb Haemost 2015; 114: 1175-1188.
37
Dunn EJ,
Philippou H,
Ariëns RAS.
et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
38
Lados-Krupa A,
Konieczynska M,
Chmiel A.
et al. Increased Oxidation as an Additional Mechanism Underlying Reduced Clot Permeability and Impaired Fibrinolysis in Type 2 Diabetes. J Diabetes Res 2015; 2015: 456189
40
Gerstein H,
Jaeschke R.
Drugs in diabetes in 2016 , changes in endocrinology in 2014. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke. Pol Arch Med Wewn 2016; 126: 907-908.
